Immune to Cancer: The CRI Blog
-
CRI Funded Scientist
Megan S. Molina, PhD
One major goal of cancer therapy is to drive elimination of tumors by harnessing the immune system…. -
CRI Funded Scientist
Alessandro Migliara, PhD
The T cells of our immune system have a “license to kill” and can be genetically reprogrammed… -
CRI Funded Scientist
Lauren B. Banks, MD, PhD
Sarcomas are rare cancers from the body’s connective tissues. Desmoplastic small round cell tumor (DSRCT) is a… -
CRI Funded Scientist
Elizabeth A. Mittendorf, MD, PhD
Immunotherapy has revolutionized the management of patients diagnosed with triple negative breast cancer (TNBC), with anti-PD-1 checkpoint blockade now standard… -
CRI Funded Scientist
Alexandra G. Moyzis, PhD
T cells are part of the adaptive immune response and play a critical role in killing cancer… -
CRI Funded Scientist
Xiaohan Ning, PhD
Spreading of cancer cells from primary tumors to healthy organs causes over 90% of cancer deaths. Cancer… -
CRI Funded Scientist
Lewis Zhichang Shi, MD, PhD
Over the past decade, immune checkpoint blockers (ICBs) such as anti-CTLA-4 and anti-PD-1 have rapidly emerged as… -
CRI Funded Scientist
Aaron van Loon, PhD
Neutrophils are fast-moving innate immune cells that play important roles in the initiation and progression of multiple… -
CRI Funded Scientist
Alejandro V. Villagra, PhD
Recent reports have shown that M2-like macrophages in tumors from patients treated with immune checkpoint blockade (ICB)…
Join CRI in Shaping the Future of Immunotherapy
Support the pioneering work of CRI in advancing immunotherapy.